Jean-Claude Bystryn 1938-2010. An obituary.

Jean-Claude Bystryn, M.D., passed away on 19 August, 2010. Dr. Bystryn's research interests encompassed a large group of dermatologic conditions. He has earned a worldwide recognition for his innovative works on autoimmune blistering diseases, melanoma and alopecia areata. The most significant impact Dr. Bystryn's research has made is on our understanding of the mechanisms of epidermal cell detachment (acantholysis) in pemphigus and development of adequate treatment. During the last decade, he chaired the Medical Advisory Board of the International Pemphigus and Pemphigoid Foundation. Dr. Bystryn was an innovative physician-scientist whose scientific contributions will be long recalled and admired both by patients and colleagues.

[1]  R. Lew,et al.  Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma , 2010, Cancer.

[2]  A. Troxel,et al.  Reliability and convergent validity of two outcome instruments for pemphigus. , 2009, The Journal of investigative dermatology.

[3]  M. Pittelkow,et al.  Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis , 2009, Experimental dermatology.

[4]  J. Bystryn,et al.  An alternate explanation for the decrease in pemphigus antibodies with combination treatment of double-filtration plasmapheresis and IVIg. , 2009, EJD. European journal of dermatology.

[5]  J. Bystryn,et al.  Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. , 2008, Archives of dermatology.

[6]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[7]  J. Bystryn,et al.  Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. , 2008, Archives of dermatology.

[8]  E. Beutner,et al.  Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. , 2008, Journal of the American Academy of Dermatology.

[9]  J. Bystryn,et al.  A novel explanation for acantholysis in pemphigus vulgaris: the basal cell shrinkage hypothesis. , 2006, Journal of the American Academy of Dermatology.

[10]  J. Bystryn,et al.  IVI g TREATMENT OF PEMPHIGUS: how it works and how to use it. , 2005, The Journal of investigative dermatology.

[11]  M. Alexiades-Armenakas,et al.  Tumid lupus erythematosus: criteria for classification with immunohistochemical analysis. , 2003, Arthritis and rheumatism.

[12]  D. Roses,et al.  Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  J. Bystryn,et al.  Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. , 2000, Archives of dermatology.

[14]  J. Sundberg,et al.  Alopecia areata: an autoimmune disease? , 1999, Experimental dermatology.

[15]  J. Bystryn,et al.  Methotrexate as an adjuvant treatment for pemphigus vulgaris. , 1999, Archives of dermatology.

[16]  J. Bystryn.  Is mycophenolic acid effective for the treatment of pemphigus? , 1999, Archives of dermatology.

[17]  J. Bystryn,et al.  Vitiligo antibodies are not directed to tyrosinase. , 1999, Archives of dermatology.

[18]  J. Bystryn.  Immune mechanisms in vitiligo. , 1997, Clinics in dermatology.

[19]  J. Bystryn,et al.  Sensitivity of indirect immunofluorescence, substrate specificity, and immunoblotting in the diagnosis of pemphigus. , 1997, Journal of the American Academy of Dermatology.

[20]  J. Bystryn,et al.  The adjuvant therapy of pemphigus. An update. , 1996, Archives of dermatology.

[21]  J. Buyon,et al.  Heterogeneity in the expression of Ro and La antigens in human skin. , 1995, Arthritis and rheumatism.

[22]  J. Bystryn,et al.  Characterization of vitiligo antigens. , 1995, Pigment cell research.

[23]  J. Bystryn,et al.  A novel bullous pemphigoid antigen (BP125) located in the deeper layers of the basement membrane zone. , 1994, Archives of dermatology.

[24]  J. Bystryn,et al.  Association of tissue-fixed cytoplasmic deposits of immunoglobulin in epidermal keratinocytes with lupus erythematosus. , 1993, Archives of dermatology.

[25]  J. Bystryn,et al.  Immunofluorescence abnormalities in lichen planopilaris. , 1992, Archives of dermatology.

[26]  R. Phelps,et al.  Regional variation in the expression of pemphigus foliaceus, pemphigus erythematosus, and pemphigus vulgaris antigens in human skin. , 1991, The Journal of investigative dermatology.

[27]  J. Bystryn,et al.  Identification of a 160-kD molecule as a component of the basement membrane zone and as a minor bullous pemphigoid antigen. , 1990, The Journal of investigative dermatology.

[28]  J. Bystryn,et al.  Epidermolysis bullosa acquisita. Incidence in patients with basement membrane zone antibodies. , 1990, Archives of dermatology.

[29]  J. Bystryn,et al.  Heterogeneity of pemphigus vulgaris antigens. , 1987, Archives of dermatology.

[30]  G. Naughton,et al.  Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. , 1986, Journal of the American Academy of Dermatology.

[31]  J. Bystryn,et al.  Identification and purification of 115- and 125-kilodalton cell surface human melanoma-associated antigens. , 1986, Journal of the National Cancer Institute.

[32]  M. Sabolinski,et al.  Regional variation in the expression of bullous pemphigoid antigen and location of lesions in bullous pemphigoid. , 1984, The Journal of investigative dermatology.

[33]  G. Naughton,et al.  Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. , 1983, The Journal of investigative dermatology.

[34]  J. Bystryn,et al.  Variability of the lupus band test. Results in 18 patients with systemic lupus erythematosus. , 1983, Archives of dermatology.

[35]  G. Naughton,et al.  Antibodies to normal human melanocytes in vitiligo , 1983, The Journal of experimental medicine.

[36]  N. Orentreich,et al.  Direct immunofluorescence studies in alopecia areata and male pattern alopecia. , 1979, The Journal of investigative dermatology.

[37]  J. Bystryn,et al.  Identification and solubilization of iodinated cell surface human melanoma associated antigens , 1977, International journal of cancer.

[38]  J. Bystryn.  Release of tumor-associated antigens by murine melanoma cells. , 1976, Journal of immunology.

[39]  J. Bystryn,et al.  Pemphigus Foliaceus: Subcorneal Intercellular Antibodies of Unique Specificity , 1974 .

[40]  J. Uhr,et al.  Sepcific removal of in vivo antibody by extracorporeal circulation over an immunoadsorbent in gel. , 1971, The Journal of clinical investigation.

[41]  J. Uhr,et al.  REGULATION OF ANTIBODY FORMATION BY SERUM ANTIBODY , 1970, Journal of Experimental Medicine.

[42]  D. Tobin,et al.  Hair follicle structures targeted by antibodies in patients with alopecia areata. , 1997, Archives of dermatology.

[43]  J. Bystryn,et al.  Clinical activity of a polyvalent melanoma antigen vaccine. , 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[44]  J. Bystryn,et al.  Identification of melanoma cell surface antigens immunogenic in mice. , 1994, Cancer biotherapy.

[45]  J. Bystryn,et al.  Identification of cicatricial pemphigoid antigens. , 1992, Archives of dermatology.

[46]  J. Bystryn,et al.  Heterogeneity of pemphigoid antigens. , 1983, The Journal of investigative dermatology.

[47]  J. Bystryn.  Immunofluorescence studies in transient acantholytic dermatosis (Grover's disease). , 1979, The American Journal of dermatopathology.

[48]  J. Bystryn,et al.  Epidermal cytoplasmic antibodies: incidence and type in normal persons and patients with melanoma. , 1976, The Journal of investigative dermatology.